Cohance Lifesciences Limited shareholders have approved the appointment of Mr. Umang Vohra as Chairman and Group Chief Executive Officer, effective May 1 and May 20, 2026, respectively. The postal ballot results, declared on June 14, 2026, also sanctioned the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' and the payment of remuneration to Mr. Vohra exceeding the limits prescribed under Section 197 of the Companies Act, 2013.

The remote e-voting process, conducted by KFin Technologies Limited, commenced on May 15, 2026, and concluded on June 13, 2026. Mr. DVM Gopal of M/s. DVM & Associates LLP served as the Scrutinizer for the process. The resolutions were passed with the required majority, though public institutions showed significant opposition to the remuneration and stock option grant proposals.

Voting Results Summary

The postal ballot sought approval for five special and ordinary resolutions. While the appointment of Mr. Vohra received overwhelming support, resolutions concerning remuneration and stock options faced notable dissent from public institutional shareholders.

Key Approvals

The members approved the appointment of Mr. Umang Vohra (DIN: 02296740) as Chairman of the Company with effect from May 1, 2026, and as Group Chief Executive Officer with effect from May 20, 2026. Additionally, the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' was approved, along with its extension to unlisted subsidiary companies.

Shareholders also authorized the grant of stock options equal to or exceeding 1% of the issued capital of the Company in a single financial year. The record date for determining eligibility was May 8, 2026. The detailed scrutinizer's report has been made available on the company's website.

Cohance Lifesciences management will engage with analysts and institutional investors at two separate conferences scheduled in Mumbai during June 2026. The company confirmed that no unpublished price-sensitive information will be shared during these interactions.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cohance Lifesciences disclosed the schedule for the upcoming meetings. The management will participate in both group and one-on-one sessions at the events.

Conference Schedule

The company noted that the schedule for these meetings is subject to change due to exigencies on the part of analysts, institutional investors, or the company. The intimation was signed by Sisir K. Mishra, Company Secretary & Compliance Officer.